MetaCap

Cartesian Therapeutics Inc. Company Profile

NASDAQ: RNACHealth CareBiotechnology: Pharmaceutical PreparationsUSD

6.14+0.25 (+4.24%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

Cartesian Therapeutics at a glance

Cartesian Therapeutics Inc. (NASDAQ: RNAC) is a Biotechnology: Pharmaceutical Preparations company in the Health Care sector headquartered in Frederick, MD. Cartesian Therapeutics is led by Dr. Carsten Brunn Ph.D. and employs about 75 people. The company's shares have traded publicly since 2016.

At a market capitalization of $187.3 million, it is considered a small-cap company. Its SEC Central Index Key (CIK) is 0001453687, which identifies the company's filings on EDGAR.

Summary generated from market data by MetaCap's automated system. Methodology

What does Cartesian Therapeutics do?

Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company's lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis. It is also developing Descartes-15, an autologous B cell maturation antigen (BCMA) that is in phase 1 trials directed mRNA CAR-T to treat patients with multiple myeloma. The company is headquartered in Frederick, Maryland.

Business description based on the company's public filings.

Company information

Legal name
Cartesian Therapeutics Inc.
Ticker
NASDAQ: RNAC
Industry
Biotechnology: Pharmaceutical Preparations
CEO
Dr. Carsten Brunn Ph.D.
Employees
75
Headquarters
7495 New Horizon Way, Frederick, MD, United States
Phone
301 348 8698
IPO year
2016
Market cap
$187.29M
SEC CIK
0001453687
Latest annual report
10-K · Mar 9, 2026

Companies similar to Cartesian Therapeutics

RNAC peer companies
CompanyPrice% ChgMarket capCompare
ANTXAN2 Therapeutics Inc.5.08-2.68%$192.75Mvs RNAC
WHWKWhitehawk Therapeutics Inc.3.07-1.60%$181.16Mvs RNAC
ACIUAC Immune SA1.95-8.45%$193.88Mvs RNAC
SLGLSol-Gel Technologies Ltd.55.17+2.02%$180.63Mvs RNAC
ADCTADC Therapeutics SA1.28-1.54%$180.05Mvs RNAC
YARWYarrow Bioscience Inc.12.90-9.35%$196.53Mvs RNAC
BIOABioAge Labs Inc.4.28-9.13%$196.67Mvs RNAC
NATRNature's Sunshine Products Inc.10.18+0.10%$176.41Mvs RNAC

Related